InflaRx Past Earnings Performance
Past criteria checks 0/6
InflaRx has been growing earnings at an average annual rate of 4.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 95.6% per year.
Key information
4.6%
Earnings growth rate
23.7%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 95.6% |
| Return on equity | -57.1% |
| Net Margin | -44,447.5% |
| Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How InflaRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -47 | 19 | 33 |
| 31 Mar 24 | 0 | -41 | 18 | 34 |
| 31 Dec 23 | 0 | -43 | 17 | 41 |
| 30 Sep 23 | 0 | -35 | 15 | 41 |
| 30 Jun 23 | 0 | -35 | 14 | 42 |
| 31 Mar 23 | 0 | -27 | 14 | 42 |
| 31 Dec 22 | 0 | -29 | 15 | 38 |
| 30 Sep 22 | 0 | -34 | 15 | 39 |
| 30 Jun 22 | 0 | -38 | 15 | 41 |
| 31 Mar 22 | 0 | -54 | 13 | 41 |
| 31 Dec 21 | 0 | -46 | 12 | 36 |
| 30 Sep 21 | 0 | -42 | 12 | 31 |
| 30 Jun 21 | 0 | -37 | 9 | 27 |
| 31 Mar 21 | 0 | -32 | 9 | 23 |
| 31 Dec 20 | 0 | -34 | 8 | 26 |
| 30 Sep 20 | 0 | -39 | 9 | 31 |
| 30 Jun 20 | 0 | -46 | 10 | 39 |
| 31 Mar 20 | 0 | -52 | 12 | 44 |
| 31 Dec 19 | 0 | -53 | 13 | 45 |
| 30 Sep 19 | 0 | -50 | 13 | 43 |
| 30 Jun 19 | 0 | -42 | 14 | 35 |
| 31 Mar 19 | 0 | -29 | 13 | 27 |
| 31 Dec 18 | 0 | -30 | 13 | 25 |
| 30 Sep 18 | 0 | -31 | 12 | 22 |
| 30 Jun 18 | 0 | -29 | 10 | 19 |
| 31 Mar 18 | 0 | -31 | 8 | 17 |
| 31 Dec 17 | 0 | -24 | 5 | 14 |
| 30 Sep 17 | 0 | -17 | 3 | 11 |
| 30 Jun 17 | 0 | -15 | 3 | 9 |
| 31 Mar 17 | 0 | -12 | 2 | 7 |
| 31 Dec 16 | 0 | -9 | 2 | 5 |
Quality Earnings: IFRX N is currently unprofitable.
Growing Profit Margin: IFRX N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IFRX N is unprofitable, but has reduced losses over the past 5 years at a rate of 4.6% per year.
Accelerating Growth: Unable to compare IFRX N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IFRX N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Return on Equity
High ROE: IFRX N has a negative Return on Equity (-57.07%), as it is currently unprofitable.